natgillin/translations-raw huggingface dataset:
- Øvrige indholdsstoffer: trometamol, natriumchlorid, hypromellose, renset vand. 
- The other ingredients are trometamol; sodium chloride; hypromellose; purified water.
Korneal limbale mononucleære celle-infiltrater blev påvist hos 1/4 hanaber behandlet med 0,5 mg/ml, og i 4/4 han- og 1/4 hunaber behandlet med 1,0 mg/ml. 
Corneal limbal mononuclear cell infiltrates were noted in 1/4 male monkeys treated with 0.5 mg/ml and in 4/4 males and 1/4 females treated with 1.0 mg/ml.
Det skal du vide, før du begynder at bruge Emadine Sådan skal du bruge Emadine Bivirkninger 
What EMADINE is and what it is used for What you need to know before you use EMADINE How to use EMADINE
Brug et spejl hvis det hjælper. 
• Bring the container tip close to the eye. Use the mirror if it helps.
Kassér enkeltdosisbeholderen umiddelbart efter brug Kassér de ikke anvendte enkeltdosisbeholdere 7 dage efter åbning af folieposen 
You must throw away the container as soon as you have used it. Once the foil wrapper has been opened any unused containers must be thrown away one week after you first opened it.
I tilfælde af uagtsom indtagelse indholdet af mange EMADINE enkelt dosisbeholdere kan der forekomme en søvndyssende virkning. 
In case of the deliberate ingestion of the contents of many unit doses of EMADINE, sedative effects may occur and the potential of emedastine to increase the QT interval should be borne in mind and appropriate monitoring and management should be implemented.
emedastin 
Excipients
Scleral mononucleære celle-infiltrater blev fundet i 1/4 han-og 1/4 hunaber behandlet med 0,5 mg/ml og i 2/4 han-og 1/4 hunaber behandlet med 1,0 mg/ml. 
Scleral mononuclear cell infiltrates were present in 1/4 males and 1/4 females treated with 0.5 mg/ml and in 2/4 males and 1/4 females treated with 1.0 mg/ml.
EMADINE 0,5 mg/ml øjendråber, opløsning i enkeltdosisbeholder emedastin 
EMADINE 0.5 mg/ml eye drops, solution, single-dose container emedastine
Små mængder saltsyre og/eller natriumhydroxid kan være tilsat for at justere pH 
Tiny amounts of hydrochloric acid or sodium hydroxide are sometimes added to keep acidity levels (pH levels) normal
Til okulær brug 
Ocular use
- Øvrige indholdsstoffer: Benzalkoniumchlorid, trometamol, natriumchlorid, hypromellose, renset vand. 
- The other ingredients are benzalkonium chloride, trometamol; sodium chloride; hypromellose;
EMADINE 0,5 mg/ml øjendråber, opløsning emedastin 
EMADINE 0.5 mg/ml eye drops, solution emedastine
Enkeltdosisbeholder 
Single-dose container
Scleral mononucleære celle-infiltrater blev fundet i 1/4 han- og 1/4 hunaber behandlet med 0,5 mg/ml og i 2/4 han- og 1/4 hunaber behandlet med 1,0 mg/ml Middel peak plasma-koncentration var omkring 1 ng/ml og 2 ng/ml ved behandling med henholdsvis 0,5 mg/ml og 1,0 mg/ml. 
Scleral mononuclear cell infiltrates were present in 1/4 males and 1/4 females treated with 0.5 mg/ml and in 2/4 males and 1/4 females treated with1.0 mg/ml.
EMADINE 0,5 mg/ml, øjendråber, opløsning. 
EMADINE 0.5 mg/ml, eye drops, solution
Ki er henholdsvis 1.3 nM, 49.064 nM og 12.430 nM. In vivo topikal okulær administration af emedastin giver en koncentrationsafhængig hæmning af den histaminstimulerede konjunktivalvaskulære permeabilitet. 
In vivo topical ocular administration of emedastine produces a concentration-dependent inhibition of histamine-stimulated conjunctival vascular permeability.
Foliepose 
Posology
Vend> 
Now turn over>
Europa-Kommissionen udstedte en markedsføringstilladelse med gyldighed i hele Den Europæiske Union for Procysbi den 06.09.2013 
The European Commission granted a marketing authorisation valid throughout the European Union for Procysbi on 06.09.2013.
Dette er et sammendrag af den europæiske offentlige vurderingsrapport (EPAR) for Procysbi. 
This is a summary of the European public assessment report (EPAR) for Procysbi.
Indholdet var 0,51 nmol/mg med Procysbi, sammenholdt med 0,44 nmol/mg med Cystagon. 
Levels were 0.51 nmol/mg with Procysbi, compared with 0.44 nmol/mg with Cystagon.
Da antallet af patienter med cystinose er lavt, betragtes sygdommen som “sjælden”, og Procysbi blev udpeget som ”lægemiddel til sjældne sygdomme” den 20. september 2010. 
Because the number of patients with cystinosis is low, the disease is considered ‘rare', and Procysbi was designated an ‘orphan medicine' (a medicine used in rare diseases) on 20 September 2010.
Agenturets Udvalg for Lægemidler til Mennesker (CHMP) afgjorde, at fordelene ved Procysbi er større end risiciene, og anbefalede, at det godkendes til anvendelse i EU. 
The Agency's Committee for Medicinal Products for Human Use (CHMP) decided that Procysbi's benefits are greater than its risks and recommended that it be approved for use in the EU.
Den anbefalede daglige dosis beregnes efter legemsoverflade med 1,30 g pr. m2, fordelt på to doser, der gives med 12 timers mellemrum. 
The recommended daily dose is calculated according to body surface area, as 1.30 g per m2 divided into 2 doses given every 12 hours.
Procysbi fås som enterokapsler (25 og 75 mg). 
Procysbi is available as gastroresistant capsules (25 and 75 mg).
Det vil sige, at det svarer til et “referencelægemiddel”, der indeholder samme aktive stof, men Procysbi fås i en formulering, der forsinker frigivelsen af det aktive stof i kroppen. 
This means that it is similar to a ‘reference medicine' containing the same active substance, but Procysbi is available in a formulation that allows for a delayed release of the active substance in the body.
Der er udarbejdet en risikostyringsplan for at sikre, at Procysbi anvendes så risikofrit som muligt. 
A risk management plan has been developed to ensure that Procysbi is used as safely as possible.
I en hovedundersøgelse med 43 patienter med nefropatisk cystinose var der ingen betydningsfuld forskel mellem de to lægemidler hvad angår det gennemsnitlige cystinindhold i de hvide blodlegemer ved 3 ugers behandling. 
In a main study involving 43 patients with nephropathic cystinosis, there was no meaningful difference between the average levels of cystine in white blood cells during a 3-week treatment with the two medicines.
Procysbi er et “hybridt lægemiddel”. 
Procysbi is a ‘hybrid medicine'.
Referencelægemidlet for Procysbi er Cystagon. 
The reference medicine for Procysbi is Cystagon.
Den fuldstændige EPAR for Procysbi findes på agenturets websted under: ema.europa.eu/Find medicine/Human medicines/European public assessment reports. 
The full EPAR for Procysbi can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Hvilke foranstaltninger træffes der for at sikre risikofri og effektiv anvendelse af Procysbi? 
What measures are being taken to ensure the safe and effective use of Procysbi?
“Enterokapsler” er kapsler, hvis indhold passerer gennem mavesækken uden at nedbrydes, før de når frem til tarmen. 
Gastroresistant means that the capsules' contents pass through the stomach without being broken down until they reach the intestine.
De hyppigste bivirkninger med Procysbi (som kan forekomme hos mere end 1 ud af hver 10 behandlede) er nedsat appetit, opkastning, kvalme, diarré, letargi (sløvhed) og feber. 
The most common side effects with Procysbi (which may affect more than 1 in 10 people) are loss of appetite, vomiting, nausea (feeling sick), diarrhoea, lethargy (lack of energy) and pyrexia (fever).
Hvad er Procysbi, og hvad anvendes det til? 
What is Procysbi and what is it used for?
Cystinose er en arvelig sygdom, hvor cystin, en aminosyre, der normalt findes i kroppen, ophobes i unormale mængder i cellerne, navnlig i nyrerne og øjnene, som derved beskadiges. 
Cystinosis is an inherited disease in which excess amounts of cystine, an amino acid naturally found in the body, build up within cells, especially in the kidneys and the eyes, damaging them.
Procysbi fås kun på recept, og behandlingen bør iværksættes og overvåges af en læge med erfaring i behandling af cystinose. 
Procysbi can only be obtained with a prescription and treatment should be started under the supervision of a doctor who has experience in the treatment of cystinosis.
Det er ikke en praktisk vejledning i, hvordan Procysbi bør anvendes. 
It is not intended to provide practical advice on how to use Procysbi.
Vedrørende sikkerheden fandt CHMP, at sikkerhedsprofilen for mercaptamin er velkendt, og at sikkerheden ved Procysbi forventes at svare til referencelægemidlets. 
Regarding its safety, the CHMP considered that the safety profile of mercaptamine is well established and the safety of Procysbi is expected to be similar to that of the reference medicine.
Procysbi må ikke anvendes hos personer, der er overfølsomme (allergiske) over for mercaptamin eller andre af indholdsstofferne eller over for penicillamin. 
Procysbi must not be used in people who are hypersensitive (allergic) to any form of mercaptamine or any of the other ingredients, or to penicillamine.
Procysbi, givet hver 12. time, er påvist at være mindst ligeså effektivt som Cystagon, givet hver sjette time, til at holde cystinindholdet i de hvide blodlegemer på et acceptabelt niveau (under 1 nmol hemicystin pr. mg protein i de hvide blodlegemer). 
Procysbi given every 12 hours has been shown to be at least as effective as Cystagon given every 6 hours at maintaining the amount of cystine in white blood cells at acceptable levels (less than 1 nmol hemicystine per mg of white blood cell protein).
Hvorfor blev Procysbi godkendt? 
Why is Procysbi approved?
CHMP bemærkede, at Procysbi var påvist at være mindst ligeså effektivt som Cystagon til at holde indholdet af cystin i de hvide blodlegemer på et acceptabelt niveau. 
The CHMP noted that Procysbi was shown to be at least as effective as Cystagon at maintaining the amount of cystine in white blood cells at acceptable levels.
Sammendraget af udtalelsen fra Udvalget for Lægemidler til Sjældne Sygdomme om Procysbi findes på EMA's websted under: ema.europa.eu/Find medicine/Human medicines/Rare disease designation. 
The summary of the opinion of the Committee for Orphan Medicinal Products for Procysbi can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
Procysbi må heller ikke anvendes hos kvinder, der ammer. 
It must also not be used in women who are breastfeeding.
Procysbi er et lægemiddel, der indeholder det aktive stof mercaptamin (også kaldet cysteamin). 
Procysbi is a medicine that contains the active substance mercaptamine (also known as cysteamine).
Andre oplysninger om Procysbi: 
Other information about Procysbi
Hvis du ønsker yderligere oplysninger om behandling med Procysbi, kan du læse indlægssedlen (også en del af denne EPAR) eller kontakte din læge eller dit apotek. 
For more information about treatment with Procysbi, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Det aktive stof i Procysbi, mercaptamin, reagerer med cystin og danner derved en anden aminosyre kaldet cystein, og et stof, der kaldes et cystein-cysteaminsalt. 
The active substance in Procysbi, mercaptamine, reacts with cystine to form another amino acid, called cysteine, and a compound called a cysteine-cysteamine salt.
Udvalget tog desuden i betragtning, at enteroformuleringen som følge af de længere intervaller mellem doserne ventes at øge ordinationsefterlevelse og livskvalitet hos patienter med cystinose. 
The Committee also considered that the gastroresistant formulation, due to its less frequent administration, is expected to increase compliance with treatment and the quality of life of patients with cystinosis.
Hvilke risici er der forbundet med Procysbi? 
What are the risks associated with Procysbi?
Procysbi mercaptamin 
Procysbi mercaptamine
I produktresuméet og indlægssedlen for Procysbi er der indsat sikkerhedsoplysninger baseret på denne plan, herunder passende forholdsregler, der skal følges af sundhedspersonale og patienter. 
Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Procysbi, including the appropriate precautions to be followed by healthcare professionals and patients.
Cystinindholdet i de hvide blodlegemer (måles i nmol hemicystin pr. mg protein de i hvide blodlegemer) eller alternativt koncentrationen af mercaptamin i blodet skal overvåges, og dosis tilpasses derefter. 
Cystine levels in white blood cells (which are measured as nmol hemicystine per mg white blood cell protein), or alternatively mercaptamine concentration in the blood, should be monitored and used to adjust the dose, which should never exceed 1.95 g per m2 per day.
Den fuldstændige liste over indberettede bivirkninger ved Procysbi fremgår af indlægssedlen. 
For the full list of all side effects reported with Procysbi, see the package leaflet.
Hvis du ønsker praktisk vejledning om anvendelsen af Procysbi, kan du læse indlægssedlen eller kontakte din læge eller dit apotek. 
For practical information about using Procysbi, patients should read the package leaflet or contact their doctor or pharmacist.
Dette salt er kroppen i stand til at fjerne fra cellerne, så cystinindholdet i organerne nedsættes, og skaden på organerne mindskes. 
The body is able to remove this salt from the cells.
Hvordan anvendes Procysbi? 
How is Procysbi used?
Hvordan virker Procysbi? 
How does Procysbi work?
Hvilke fordele viser undersøgelserne, at der er ved Procysbi? 
What benefits of Procysbi have been shown in studies?
Desuden skal den virksomhed, der markedsfører Procysbi, udlevere oplysningsmateriale til de læger, som forventes at ordinere lægemidlet. 
In addition, the company that markets Procysbi will provide educational material to all doctors expected to prescribe the medicine, containing important safety information including the risk that the medicine may be harmful to the unborn child.
Procysbi anvendes til behandling af nefropatisk cystinose (cystinose, der angriber nyrerne). 
It is used in patients with nephropathic (kidney) cystinosis.
Ældre (>65 år) 
Elderly (>65 years old)
Søg omgående lægehjælp. 
Get medical help immediately.
Alle sammenligninger med placebo var statistisk signifikante. 
All comparisons against placebo were statistically significant.
Jo mere aktiv du er, jo højere kaloriemål. 
The more active you are, the higher your calorie target.
Det kan være nødvendigt at afbryde behandlingen. 
It may be necessary to discontinue treatment.
Generelt optrådte de tidligt i behandlingen (inden for 3 måneder), og de fleste patienter oplevede kun en enkelt episode. 
They generally occurred early in treatment (within 3 months) and most patients experienced only one episode.
Hvis du er usikker på hvilket niveau du tilhører, så vælg Lavt aktivitetsniveau. 
If you are unsure which level you are, choose Low activity.
Hepatitis, som kan være alvorlig. 
Hepatitis that may be serious.
Derfor skal behandling med orlistat kun initieres efter nøje overvejelse af den mulige indvirkning på disse patienter. 
Therefore orlistat treatment should only be initiated after careful consideration of the possible impact in these patients.
Pakningen indeholder: 
This pack includes:
Vælg din startdato 
Choose your start date
4.5 Interaktion med andre lægemidler og andre former for interaktion Ciclosporin 
4.5 Interaction with other medicinal products and other forms of interaction Ciclosporin
Se punkt 2, advarsler og forsigtighedsregler. 
See section 2, warnings and precautions.
Nogen gange kaldes det kilokalorier eller kcal. Energi kan også måles i kilojoule, hvilket du kan se på fødevaredeklarationer. 
They are sometimes called kilocalories or kcal. Energy may also be measured in kilojoules, which you may also see on food labels.
FLERE NYTTIGE OPLYSNINGER 
FURTHER HELPFUL INFORMATION
Se tabellen senere i dette afsnit. 
See the chart further on in this section.
Dette kan potentielt medføre reduceret immunosuppressivitet. 
This could potentially lead to a decrease of immunosuppressive efficacy.
Virkninger, der kan ses i blodprøver 
Effects seen in blood tests
Systemorganklasse og hyppighed 
System organ class and frequency
Hyppighed defineres som meget almindelig (≥1/10), almindelig (≥1/100 til <1/10), ikke almindelig (≥1/1.000 til <1/100), sjælden (≥1/10.000 til <1/1.000), meget sjælden (<1/10.000), samt ikke kendt (kan ikke estimeres ud fra forhåndenværende data). 
Frequencies are defined as: very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1,000 to <1/100), rare (≥1/10,000 to <1/1,000), very rare (<1/10,000) and not known (cannot be estimated from the available data).
Der er begrænsede data om anvendelse af orlistat til ældre. 
There are limited data on the use of orlistat in the elderly.
Forsøg på dyr indicerer ingen skadelige virkninger med hensyn til fertilitet. 
Animal studies do not indicate harmful effects with respect to fertility.
Der er ingen data tilgængelige. 
No data are available.
Vælg det aktivitetsniveau der passer bedst på din daglige rutine. 
Choose the level that most closely fits your daily routine.
Den kumulative renale udskillelse af totalt orlistatrelateret materiale var < 2 % af den indgivne dosis. 
The cumulative renal excretion of total orlistat-related materials was <2% of the given dose.
I tilfælde af signifikant overdosering med orlistat anbefales det, at patienten observeres i 24 timer. 
Should a significant overdose of orlistat occur, it is recommended that the patient be observed for 24 hours.
Den daglige indtagelse af fedt, kulhydrat og protein bør fordeles mellem de tre hovedmåltider. 
The daily intake of fat, carbohydrate and protein should be distributed over three main meals.
Det betyder ikke, at tabletterne ikke virker. 
This does not mean that the tablets are not working.
Ved opbevaring i etuiet: 1 måned. 
When stored in the carry case: 1 month.
Dato for første markedsføringstilladelse: 23. juli 2007 Dato for seneste fornyelse: 29. juni 2017 
Date of first authorisation: 23rd July 2007 Date of latest renewal: 29th June 2017
Find din højde i skemaet. 
Find your height on the chart.
Det betyder ikke, at kapslerne ikke virker. 
This does not mean that the capsules are not working.
Kalorier er et mål for den energi din krop behøver. 
Calories are a measurement of the energy your body needs.
Vigtig information om nogle af de øvrige indholdsstoffer i alli Sådan skal du tage alli 
Important information about some of the ingredients of alli How to take alli
D. BETINGELSER ELLER BEGRÆNSNINGER MED HENSYN TIL EN SIKKER OG EFFEKTIV ANVENDELSE AF LÆGEMIDLET 
D. CONDITIONS OR RESTRICTIONS WITH REGARD SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT
alli anbefales ikke til personer, som tager acarbose. 
alli is not recommended for people taking acarbose.
• når risikostyringssystemet ændres, særlig som følge af, at der er modtaget nye oplysninger, der kan medføre en væsentlig ændring i risk/benefit-forholdet, eller som følge af, at en vigtig milepæl (lægemiddelovervågning eller risikominimering) er nået. 
• Whenever the risk management system is modified, especially as the result of new information being received that lead to a significant change to the benefit/risk profile or as the result of an important (pharmacovigilance or risk minimisation) milestone being reached
Du kan også besøge din landsspecifikke alli-hjemmeside for yderligere information om alli vægttabsprogrammet. 
You can also visit your country specific alli website for further information about the alli weight loss programme.
Tænk over, hvor meget du gerne vil tabe dig og fastsæt så et mål for dit vægttab. 
Think about how much weight you want to lose and then set a target weight.
Tag altid dette lægemiddel nøjagtigt som beskrevet i denne indlægsseddel eller efter de anvisninger, lægen eller apotekspersonalet har givet dig. 
Always take this medicine exactly as described in this leaflet or as your doctor or pharmacist has told you.
Måske skal du holde op med at tage alli. 
You may need to stop taking alli.
BILAG II A. FREMSTILLER ANSVARLIG FOR BATCHFRIGIVELSE B. BETINGELSER ELLER BEGRÆNSNINGER VEDRØRENDE UDLEVERING OG ANVENDELSE C. ANDRE FORHOLD OG BETINGELSER FOR MARKEDSFØRINGSTILLADELSEN D. BETINGELSER ELLER BEGRÆNSNINGER MED HENSYN TIL SIKKER OG EFFEKTIV ANVENDELSE AF LÆGEMIDLET 
ANNEX II A. MANUFACTURER(S) RESPONSIBLE FOR BATCH RELEASE B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT
Hvis dette opstår skal patienten konsultere en læge. 
If this occurs, the patient should consult a doctor.
Dog bør en eventuel risiko undgås (se pkt. 
However, any possible risk should be avoided (see section 6.6).
Selv om vægttab blev vurderet i løbet af de 12 måneders behandling i begge forsøg, opstod de væsentligste vægttab inden for de først 6 måneder. 
Although weight loss was assessed during 12 months of treatment in both studies, most weight loss occurred within the first 6 months.
Denne risiko er øget hos patienter med underliggende kronisk nyresygdom og/eller volumendepletion. 
This risk is increased in patients with underlying chronic kidney disease and/or volume depletion.
Brug af anden medicin sammen med alli alli kan måske påvirke nogle lægemidler, som du har brug for at tage. 
Other medicines and alli alli may affect some medicines you have to take.
natriumlaurilsulfat, talcum. 
sodium laurilsulfate, talc.
Stop med at tage tabletterne. 
Stop taking the tablets.
Tiden til fuldstændig udskillelse (fækal plus renal) var 3-5 dage. 
The time to reach complete excretion (faecal plus urinary) was 3 to 5 days.
- acarbose (et lægemiddel, som anvendes til behandling af type 2-sukkersyge). 
- acarbose, (an anti-diabetic medicine used to treat type 2 diabetes mellitus).
Ca. 97 % af den indgivne dosis blev udskilt i fæces, og heraf var 83 % uomdannet orlistat. 
Approximately 97% of the administered dose was excreted in faeces and 83% of that as unchanged orlistat.
Dette lægemiddel må ikke anvendes af børn og teenagere under 18 år. 
This medicine must not be taken by children and adolescents under 18 years old.
- Lavt aktivitetsniveau betyder, at du dagligt udfører lidt eller ingenting af det følgende: gang, trappegang, havearbejde, eller andre fysiske aktiviteter. 
- Low activity means you do little or no walking, climbing stairs, gardening, or other physical activity on a daily basis.
Stop med at tage kapslerne. 
Stop taking the capsules.
Povidon (E1201) (K-værdi 30) 
Povidone (E1201) (K-value 30)
Kan forekomme hos op til 1 ud af 10 personer - Mavepine (abdominalsmerter). 
These may affect up to 1 in 10 people - Stomach (abdominal) pain.
Behandlingens varighed må ikke overskride 6 måneder. 
Treatment should not exceed 6 months.
Effekten af orlistat medfører en øgning af fækalt fedt allerede 24 til 48 timer efter indgift. 
The effect of orlistat results in an increase in faecal fat as early as 24 to 48 hours after dosing.
Dette kan skyldes et fald i absorptionen af jodsalte og/eller levothyroxin. 
This could be due to a decreased absorption of iodine salts and/or levothyroxine.
- medicin mod epilepsi, da enhver ændring i hyppighed og alvor af dine kramper skal diskuteres med din læge. 
- a medicine for epilepsy as any changes in the frequency and severity of your convulsions should be discussed with your doctor.
- Du må ikke tage 2 tabletter på samme tid for at “indhente” den tablet du glemte at tage. 
- Do not take 2 tablets at the same time to make up for a forgotten tablet.
- er under 18 år. 
- if you are under 18 years old.
Orlistat er en kraftig, specifik og langtidsvirkende hæmmer af gastrointestinale lipaser. 
Orlistat is a potent, specific and long-acting inhibitor of gastrointestinal lipases.
Sådanne kostbetingede gener kan være et signal om, at du har indtaget mere fedt, end du burde. 
Such diet-related treatment effects may be a signal that you have eaten more fat than you should have done.
Orlistat fordeler sig minimalt i erytrocytter. 
Orlistat minimally partitions into erythrocytes.
Hvis du har glemt at tage alli 
If you forget to take alli
For at hjælpe dig til at nå dit mål for vægttabet skal du fastsætte to daglige mål: Et for kalorier og et for fedt. 
To help you reach your weight-loss goal you need to set two daily targets, one for calories and one for fat.